New approaches in metastatic melanoma: biological and molecular targeted therapies (Q36817127)

16 August 2017

1 reference

title

New approaches in metastatic melanoma: biological and molecular targeted therapies (English)

1 reference

16 August 2017

1 reference

Ferdy J Lejeune

1

1 reference

16 August 2017

Donata Rimoldi

series ordinal

2

1 reference

16 August 2017

Daniel Speiser

series ordinal

3

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

701-713

1 reference

Metastatic melanoma: chemotherapy

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Classical chemotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Systemic chemotherapy for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Chemotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Functional and therapeutic significance of Akt deregulation in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

BRAF somatic mutations in malignant melanoma and melanocytic naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Determinants of BRAF mutations in primary melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Chemotherapy and targeted therapy combinations in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Vaccination: role in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Dendritic cells in melanoma immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Targeting antigens to dendritic cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

CD4+CD25+ regulatory T cells in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Gene-based therapy of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

siRNA, miRNA and HIV: promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

microRNAs exhibit high frequency genomic alterations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Cancer stem cells: an old idea--a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

A tumorigenic subpopulation with stem cell properties in melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

The chemokine system: tuning and shaping by regulation of receptor expression and coupling in polarized responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Human melanoma metastases express functional CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

MITF: master regulator of melanocyte development and melanoma oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

c-Met expression is regulated by Mitf in the melanocyte lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

The WNT/Beta-catenin pathway in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Notch and NOXA-related pathways in melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.701

21 January 2018

Identifiers

DOI

10.1586/14737140.7.5.701

1 reference

16 August 2017

1 reference